Large and Small-scale Bioprocessing

Global Large and Small-scale Bioprocessing Market to Reach US$163.5 Billion by 2030

The global market for Large and Small-scale Bioprocessing estimated at US$78.1 Billion in the year 2024, is expected to reach US$163.5 Billion by 2030, growing at a CAGR of 13.1% over the analysis period 2024-2030. Bioreactors / Fermenters, one of the segments analyzed in the report, is expected to record a 15.8% CAGR and reach US$51.7 Billion by the end of the analysis period. Growth in the Cell Culture Products segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$21.3 Billion While China is Forecast to Grow at 18.0% CAGR

The Large and Small-scale Bioprocessing market in the U.S. is estimated at US$21.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$35.4 Billion by the year 2030 trailing a CAGR of 18.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.3% and 11.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global Large and Small-scale Bioprocessing Market – Key Trends & Drivers Summarized

How Are Technological Innovations Transforming the Bioprocessing Industry?

Bioprocessing, whether on a large or small scale, has undergone rapid advancements, driven by the need for more efficient, cost-effective, and scalable solutions in the biopharmaceutical, food, and industrial biotechnology sectors. The integration of automation, artificial intelligence, and real-time monitoring systems has significantly enhanced process optimization and quality control. Continuous bioprocessing, an emerging trend, is revolutionizing large-scale production by reducing downtime, increasing throughput, and minimizing waste. Single-use bioreactors and disposable technologies have gained traction, particularly in small-scale bioprocessing, as they lower contamination risks and streamline operational flexibility. The advent of modular bioprocessing systems has further facilitated adaptability, allowing manufacturers to rapidly scale up or down based on demand. Moreover, advancements in cell culture techniques, including the development of genetically engineered cell lines and 3D bioprinting applications, have bolstered process efficiency and productivity. Digital twins—virtual replicas of bioprocessing systems—are now being utilized to simulate process scenarios, optimize parameters, and predict performance outcomes. Additionally, improvements in upstream processing, including high-density cell culture strategies, have significantly increased yields while reducing raw material costs. On the downstream side, next-generation chromatography techniques and continuous purification systems are streamlining recovery processes and enhancing product consistency. As the industry continues to embrace technological innovations, large and small-scale bioprocessing is becoming more sophisticated, paving the way for improved product quality, regulatory compliance, and scalability.

Why Is the Bioprocessing Industry Experiencing a Shift in Market Demand?

The bioprocessing industry has seen a dramatic shift in market demand, primarily fueled by the rising prevalence of biologics, personalized medicine, and sustainable biomanufacturing. The increasing focus on cell and gene therapies has led to higher investments in small-scale bioprocessing, as these treatments require precise and controlled production environments. At the same time, large-scale bioprocessing is witnessing significant growth due to the expanding pipeline of monoclonal antibodies, vaccines, and recombinant proteins. The global pandemic accelerated the need for robust and scalable bioprocessing solutions, highlighting the importance of rapid response manufacturing capabilities. Furthermore, the shift toward plant-based and cultured food products has propelled the demand for bioprocessing techniques in the food industry. Industrial biotechnology applications, such as biofuels and enzyme production, have also contributed to market expansion. Additionally, regulatory bodies are increasingly advocating for process intensification and risk mitigation strategies, further driving investments in advanced bioprocessing technologies. The growing preference for contract development and manufacturing organizations (CDMOs) is another key factor shaping demand, as companies look to external partners to scale production while maintaining quality and compliance. As consumer awareness around sustainability rises, there is also increasing demand for greener bioprocessing solutions, including the use of renewable feedstocks and energy-efficient processes. These shifts in market demand underscore the need for bioprocessing companies to adopt flexible, scalable, and innovative production strategies to remain competitive.

How Are Industry Players Responding to Challenges in Bioprocessing?

Despite significant advancements, the bioprocessing industry faces several challenges, prompting industry players to adopt strategic solutions. One of the major hurdles in large-scale bioprocessing is maintaining process efficiency while ensuring high product quality and consistency. To address this, companies are investing in process analytical technologies (PAT), enabling real-time monitoring and control of critical process parameters. Supply chain disruptions, particularly for single-use components and raw materials, have prompted manufacturers to diversify sourcing strategies and develop local supply chains. Bioprocessing facilities are also implementing flexible production models, including hybrid bioprocessing systems that integrate both single-use and stainless-steel technologies to optimize operational efficiency. Small-scale bioprocessing, on the other hand, faces challenges related to scalability and cost constraints. To overcome these issues, companies are leveraging microfluidic bioreactors, which allow precise control over cell culture conditions while using minimal resources. Workforce shortages and the need for specialized expertise have led to an increased reliance on digital training platforms and AI-driven decision support systems. Additionally, regulatory compliance remains a key concern, particularly as new biologics and advanced therapies emerge. Companies are investing in automated data management systems to ensure compliance with evolving regulatory requirements while reducing documentation errors. By proactively addressing these challenges, bioprocessing companies are strengthening their resilience, ensuring sustainable growth, and maintaining a competitive edge in a rapidly evolving industry.

What’s Driving the Expansion of the Large and Small-scale Bioprocessing Market?

The growth in the bioprocessing market is driven by several factors, including the rising adoption of biologics, increased funding for biopharmaceutical R&D, and technological advancements in manufacturing processes. The growing demand for biosimilars, driven by patent expirations of blockbuster biologics, has accelerated investments in large-scale bioprocessing facilities. The expansion of the contract biomanufacturing sector has further contributed to market growth, as pharmaceutical companies seek cost-effective and scalable production solutions. Small-scale bioprocessing is benefiting from the increasing demand for personalized medicine and cell-based therapies, which require flexible and precise manufacturing approaches. Additionally, the rising prevalence of chronic diseases, including cancer and autoimmune disorders, has heightened the need for advanced biologics, fueling investments in both upstream and downstream bioprocessing technologies. Governments and private investors are heavily funding biomanufacturing initiatives, particularly in regions such as North America, Europe, and Asia-Pacific, further accelerating market expansion. The transition toward continuous manufacturing and smart bioprocessing solutions has also played a significant role in market growth, improving efficiency while reducing production costs. Moreover, sustainability concerns are prompting companies to develop eco-friendly bioprocessing solutions, including waste reduction strategies and renewable energy integration. The increasing digitization of bioprocessing operations, driven by AI, big data analytics, and cloud-based solutions, is further streamlining production workflows and enhancing decision-making processes. As the industry continues to evolve, these growth drivers will shape the future of bioprocessing, ensuring greater accessibility, affordability, and efficiency in the production of biologics and other biotechnology-based products.

SCOPE OF STUDY:

The report analyzes the Large and Small-scale Bioprocessing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Bioreactors / Fermenters, Cell Culture Products, Filtration Assemblies, Bioreactors Accessories, Bags & Containers, Other Products); Workflow (Downstream Processing Workflow, Fermentation Workflow, Upstream Processing Workflow); Use Type (Multi-Use Type, Single-Use Type); Mode (In-house Mode, Outsourced Mode); Application (Biopharmaceuticals Application, Specialty Industrial Chemicals Application, Environmental Aids Application)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Amgen Inc.
• Applikon Biotechnology
• Biogen Inc.
• Bristol-Myers Squibb Company
• Danaher Corporation
• Eppendorf AG
• FUJIFILM Diosynth Biotechnologies
• GE Healthcare Life Sciences
• Gilead Sciences, Inc.
• Lonza Group AG
• Merck KGaA
• Moderna, Inc.
• Novartis International AG
• Novasep Holding SAS
• Pall Corporation
• Regeneron Pharmaceuticals, Inc.
• Rentschler Biopharma SE
• Sartorius AG
• Thermo Fisher Scientific Inc.
• Vertex Pharmaceuticals Incorporated

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.